Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.35 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.35 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.33 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.31 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.31 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.31 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.31 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL544525 | 1.00 | DAO (0.35) | DAOHDAC8HDAC6AURKAAURKB | |
| SCHEMBL14337371 | 0.84 | — | — | |
| SCHEMBL3194313 | 0.81 | DAO (0.35) | DAOHDAC8HDAC6AURKAAURKB | |
| SCHEMBL20280328 | 0.78 | MAPT (0.61) | DAOHDAC8HDAC6KDM4EGAA | |
| SCHEMBL3221479 | 0.77 | — | — | |
| SCHEMBL967615 | 0.77 | — | — | |
| SCHEMBL19921043 | 0.76 | ALDH1A1 (0.36) | — | |
| SCHEMBL14337293 | 0.73 | ALDH1A1 (0.33) | GAA | |
| SCHEMBL78890 | 0.71 | — | — | |
| SCHEMBL2776642 | 0.71 | ALDH1A1 (0.38) | FKBP5NAPRTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4355792-A2 | TRIAZOLE CONTAINING POLYMERS AND METHODS OF USE THEREOF | William Marsh Rice University (US) | 2024-04-24 | — | — | EP | disclosed |
| EP-4320170-A1 | INTERFACIAL SEEDING OF CELLS AND PARTICLES ON SURFACES FOR DIAGNOSTICS AND THERAPEUTICS | William Marsh Rice University (US) | 2024-02-14 | — | — | EP | disclosed |
| CN-117244109-A | Vascularization device and method for implantable diagnosis and treatment | 威廉马歇莱思大学 | 2023-12-19 | — | — | CN | disclosed |
| CN-113825531-B | Vascularization device and method for implantable diagnosis and treatment | 威廉马歇莱思大学 | 2023-07-25 | — | — | CN | disclosed |
| US-20230210908-A1 | METHODS FOR IMPROVED DELIVERY OF THERAPEUTIC AGENTS | WILLIAM MARSH RICE UNIVERSITY (US) | 2023-07-06 | — | — | US | disclosed |
| US-20230130084-A1 | MODIFIED ALGINATES FOR CELL ENCAPSULATION AND CELL THERAPY | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2023-04-27 | — | — | US | disclosed |
| US-20230054899-A1 | HIGH THROUGHPUT GENETIC BARCODING AND ANALYSIS METHODS | WILLIAM MARSH RICE UNIVERSITY (US) | 2023-02-23 | — | — | US | disclosed |
| WO-2022266086-A2 | TRIAZOLE CONTAINING POLYMERS AND METHODS OF USE THEREOF | WILLIAM MARSH RICE UNIVERSITY (US) | 2022-12-22 | — | — | WO | disclosed |
| EP-4103237-A1 | METHODS FOR IMPROVED DELIVERY OF THERAPEUTIC AGENTS | William Marsh Rice University (US) | 2022-12-21 | — | — | EP | disclosed |
| US-20220333050-A1 | INTERFACIAL SEEDING OF CELLS AND PARTICLES ON SURFACES FOR DIAGNOSTICS AND THERAPEUTICS | WILLIAM MARSH RICE UNIVERSITY (US) | 2022-10-20 | — | — | US | disclosed |
| WO-1996040304-A1 | INJECTABLE HYDROGEL COMPOSITIONS | REPROGENESIS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| EP-0299010-B1 | CHIMERIC NEOMORPHOGENESIS OF ORGANS BY CONTROLLED CELLULAR IMPLANTATION USING ARTIFICIAL MATRICES | CHILDRENS MEDICAL CENTER (US) | 1996-06-19 | — | — | EP | disclosed |
| EP-0708662-A1 | INJECTABLE POLYSACCHARIDE-CELL COMPOSITIONS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1996-05-01 | — | — | EP | disclosed |
| WO-1994025079-A1 | POROUS BIODEGRADABLE POLYMERIC MATERIALS FOR CELL TRANSPLANTATION | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1994-11-10 | — | — | WO | disclosed |
| WO-1994025080-A1 | INJECTABLE POLYSACCHARIDE-CELL COMPOSITIONS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1994-11-10 | — | — | WO | disclosed |
| EP-0610423-A1 | PREVASCULARIZED POLYMERIC IMPLANTS FOR ORGAN TRANSPLANTATION. | MASSACHUSETTS INST TECHNOLOGY (US) | 1994-08-17 | — | — | EP | disclosed |
| WO-1993008850-A1 | PREVASCULARIZED POLYMERIC IMPLANTS FOR ORGAN TRANSPLANTATION | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1993-05-13 | — | — | WO | disclosed |
| EP-0299010-A4 | CHIMERIC NEOMORPHOGENESIS OF ORGANS BY CONTROLLED CELLULAR IMPLANTATION USING ARTIFICIAL MATRICES. | VACANTI JOSEPH P (US) | 1990-01-26 | — | — | EP | disclosed |
| EP-0299010-A1 | CHIMERIC NEOMORPHOGENESIS OF ORGANS BY CONTROLLED CELLULAR IMPLANTATION USING ARTIFICIAL MATRICES. | VACANTI JOSEPH P (US) | 1989-01-18 | — | — | EP | disclosed |
| WO-1988003785-A1 | CHIMERIC NEOMORPHOGENESIS OF ORGANS BY CONTROLLED CELLULAR IMPLANTATION USING ARTIFICIAL MATRICES | VACANTI JOSEPH P (US) | 1988-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230130084-A1 | MODIFIED ALGINATES FOR CELL ENCAPSULATION AND CELL THERAPY | ALG1, CD44, CD47 | DAO 2317/4885HDAC8 612/4885HDAC6 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.